Fortrea Holdings Inc

Fortrea Holdings Inc(FTRE)股票分析

$17.720

-0.627 (-3.54%)收盤時

Loading chart…
High
18.510
Open
18.380
VWAP
17.95
Vol
1.19M
Mkt Cap
2.04B
Low
17.620
Amount
21.29M
EV/EBITDA, TTM
18.08

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

AI analysis of Fortrea Holdings Inc (FTRE)

buy

Fortrea Holdings Inc is a good buy right now, trading at $18.81 with a forward P/E of 13.18, which suggests potential for growth compared to its current valuation. The recent earnings report showed a non-GAAP EPS of $0.23, beating expectations by $0.05, indicating improved profitability. However, a risk is the insider selling activity, which has increased by 267.54% over the last month, suggesting potential concerns among insiders.

估值指標

The current forward P/E ratio for Fortrea Holdings Inc (FTRE) is 13.42, compared to its 5-year average forward P/E of 23.13.

Forward P/E

Fair
5Y Average P/E
23.13
Current P/E
13.42
高估
38.84
低估
7.42

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
12.32
Current EV/EBITDA
18.08
高估
18.42
低估
6.23

Forward P/S

Fair
5Y Average P/S
0.63
Current P/S
0.64
高估
0.92
低估
0.34

Alphio AI Price Scenarios for FTRE

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%FTRE

$4.04

情境價格

B

Base

Base · 50%FTRE

$3.61

情境價格

B

Bear

Bear · 25%FTRE

$2.97

情境價格

Whales holding FTRE

C

Corvex Management LP

+ HoldingFTRE

+9.43%

3M Return

S

Sessa Capital IM, L.P.

+ HoldingFTRE

+8.59%

3M Return

B

Beck, Mack & Oliver LLC

+ HoldingFTRE

+6.53%

3M Return

A

Ausbil Investment Management Limited

+ HoldingFTRE

+1.00%

3M Return

事件時間軸

2026-07-29 (ET)

07:00:00

Raises FY26 Adjusted EBITDA Outlook to $205M-$220M

2026-06-26 (ET)

09:30:00

Nasdaq Futures Decline as Tech Stocks Weaken

07:30:00

Fortrea Appoints Jason Knoblauch as CFO

2026-05-05 (ET)

06:10:00

Fortrea Q1 Revenue $636.5M, Exceeds Expectations

資訊

FTRE FAQ — answered by Alphio AI

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Fortrea Holdings Inc is a good buy right now, trading at $18.81 with a forward P/E of 13.18, which suggests potential for growth compared to its current valuation. The recent earnings report showed a non-GAAP EPS of $0.23, beating expectations by $0.05, indicating improved profitability. However, a risk is the insider selling activity, which has increased by 267.54% over the last month, suggesting potential concerns among insiders.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始